PACS - PACS Group, Inc.
PACS Group NYSE: PACS reported a strong start to 2026, with executives citing higher occupancy, improved skilled mix and continued progress integrating acquired facilities as drivers of first-quarter performance.
PACS Group (PACS) is reaffirmed as a 'Buy' for long-term investors, following a 257% rebound from oversold lows. PACS demonstrates robust credit health with $795M liquidity, 0.1x net leverage, and strong interest coverage, supporting aggressive organic and acquisition-driven growth. Guidance for FY26 includes 8% revenue growth and 22% adjusted EBITDA growth, with margin expansion driven by facility maturation and industry consolidation opportunities.
Demand for skilled-nursing and rehabilitative services is rising. PACS is consolidating a fragmented industry.
PACS Group, Inc. (PACS) Q1 2026 Earnings Call Transcript
PACS Group, Inc. (PACS) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.17 per share a year ago.
SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the first quarter of 2026. First Quarter 2026 Financial Highlights Revenue was $1.42 billion, an increase of 11.2% over prior year. Net income was $80.7 million, an increase of $52.3 million, or 184.2% from $28.4 million in the prior-year period. Adjusted EBITDA w.
Investors interested in stocks from the Medical Services sector have probably already heard of PACS Group, Inc. (PACS) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, today announced that it intends to release its first quarter 2026 financial results on Monday, May 11, 2026. Management will host a call on Tuesday, May 12, 2026, at 11:30 a.m. ET to discuss the financial results and related information. PACS Group invites current and prospective investors to li.
SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”) today announced that independently operated subsidiaries of the Company have acquired the operations of the post-acute care facility Ridgeway Senior Living in Anchorage, Alaska. It's the fourth PACS building in the state of Alaska. As part of the transaction, PACS has acquired land adjacent to the building, with plans to build a subsequent 150-bed skilled nursing facility, with an estimated completion date.
SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS), one of the nation's largest and fastest-growing post-acute healthcare platforms, today announced the appointment of Carey P. Hendrickson as its Chief Financial Officer, effective April 27, 2026. Mr. Hendrickson brings to PACS nearly four decades of financial leadership spanning public company CFO roles in healthcare, senior living, and media — a body of work distinguished by financial discipline, strategic acuity, and a consistent.
SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS), one of the nation's largest and fastest-growing post-acute healthcare platforms, today announced the planned retirement of Mark Hancock — PACS co-founder, first CFO, and one of the principal architects behind the company's success — on June 30, 2026. Mr. Hancock co-founded PACS in 2013 alongside Jason Murray, PACS's Chairman and CEO, with just two post-acute care facilities in San Diego, CA. Under his leadership as CFO, PACS expand.
The average of price targets set by Wall Street analysts indicates a potential upside of 31% in PACS Group, Inc. (PACS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Investors looking for stocks in the Medical Services sector might want to consider either PACS Group, Inc. (PACS) or Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?
PHILADELPHIA, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Kaskela Law is investigating potential breach of fiduciary duty claims concerning PACS Group, Inc. (NYSE: PACS) (“PACS”) on behalf of the company's long-term shareholders.
PACS Group, Inc. (NYSE: PACS - Get Free Report) has been assigned a consensus rating of "Buy" from the six research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the
SHEL, XYZ, UAA, PACS and LAUR have been added to the Zacks Rank #1 (Strong Buy) List on April 14, 2026.
The average of price targets set by Wall Street analysts indicates a potential upside of 31.2% in PACS Group, Inc. (PACS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Investors interested in stocks from the Medical Services sector have probably already heard of PACS Group, Inc. (PACS) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?
Crewe Advisors LLC increased its stake in PACS Group, Inc. (NYSE: PACS) by 93.1% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,147,815 shares of the company's stock after purchasing an additional 1,035,747 shares during the quarter. PACS Group comprises about
PACS Group, Inc. (NYSE: PACS - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to